samedan logo

 
 
spacer
home > ebr > winter 2003 > peptides in metabolic diseases - peptidomics as a comprehensive profiling tool
PUBLICATIONS
European Biopharmaceutical Review

Peptides in Metabolic Diseases - Peptidomics as a Comprehensive Profiling Tool

The genotype represents a blueprint of an organism, which is used in different ways during development, adulthood and disease states. Quantitative changes in the use of genes contribute to the variability of general physiology and pathophysiology. A mutation of a gene qualitatively changes the genotype and thus may determine a predisposition for a disease. However, peptides and proteins define the actual phenotype and may reflect or even cause a pathogenic process. Therefore proteomics is regarded as a pivotal technology in defining the transition from health to disease, describing the current disease status and its progression with time. In this context, it has to be distinguished between technologies addressing proteins in general and those specifically analysing peptides.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Imke Schulte, Metabolic Syndrome Project Research Manager, Hartmut Selle, Biomarker Discovery Project Research Manager, and Peter Schulz-Knappe, CSO and Co-founder of BioVisioN

Having graduated from the University Mьnster in Biochemistry, Imke Schulte worked on molecular and cellular physiology for her doctoral thesis at the Medical School in Hannover. In 2002 she joined BioVisioN as a Project Manager, working in the medical research department with responsibility for projects in the field of the metabolic syndrome.


Hartmut Selle graduated as a Biologist from the University of Hannover in Germany. He worked as a Clinical Research Assistant for the pharmaceutical industry conducting clinical trials on disorders of the CNS, the vascular system and the gastrointestinal tract. In 1999 he joined BioVisioN as a Project Manager and has been involved in a number of projects on biomarker discovery, including Alzheimer's disease.


Peter Schulz-Knappe is one of four founders of BioVisioN. He holds a Medical degree from the University of Heidelberg, and a degree in Cell Biology from the Medical School in Hannover. He has over 20 years experience in peptide chemistry and functional analysis of peptides. As CSO he is responsible for the scientific work in the company.

spacer
Imke Schulte
spacer
spacer
spacer
Hartmut Selle
spacer
spacer
spacer
Peter Schulz-Knappe
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm Expands Relationship With Novan On Formulation Science

MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc. MedPharm has previously supported Novan by testing the companyís unique formulations using its proprietary in vitro models to optimise Novanís formulations and de-risk product development.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement